Three-year U.S. pharmacovigilance report of brodalumab (vol 34, e15105, 2021)

被引：0

|

作者：

Lebwohl

机构：

来源：

DERMATOLOGIC THERAPY | 2022年 / 35卷 / 09期

关键词：

D O I：

10.1111/dth.15664

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

收藏

页数：2

相关论文

共 5 条

[1] Three-year US pharmacovigilance report of brodalumab
Lebwohl, Mark
Leonardi, Craig
Armstrong, April
Rawnsley, Nicole
Alexander, Binu
Goehring, Earl, Jr.
Kerdel, Francisco
Jacobson, Abby
DERMATOLOGIC THERAPY, 2021, 34 (06)
[2] U.S. paper/board capacity stabilizes after three-year decline; Future growth near nil
2005, RISI (11):
[3] Three-year Clinical Performance of Two Giomer Restorative Materials in Restorations (vol 46, pg E60, 2021)
Irmak, Ozgur
OPERATIVE DENTISTRY, 2021, 46 (03) : 349 - 349
[4] A survey of U.S. public perspectives on facial recognition technology and facial imaging data practices in health and research contexts (vol 16, e0257923, 2021)
PLOS ONE, 2021, 16 (12):
[5] Single-track year-round education for improving academic achievement in U.S. K-12 schools: Results of a meta-analysis (vol 15, e1053. 2019)
Fitzpatrick, Dan
Burns, Jason
CAMPBELL SYSTEMATIC REVIEWS, 2020, 16 (04)